Publication | Open Access
Adagrasib in Non–Small-Cell Lung Cancer Harboring a <i> KRAS <sup>G12C</sup> </i> Mutation
886
Citations
22
References
2022
Year
In patients with previously treated <i>KRAS<sup>G12C</sup></i> -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals. (Funded by Mirati Therapeutics; ClinicalTrials.gov number, NCT03785249.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1